Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.

Autor: Miura K; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan., Tsujimura H; Division of Medical Oncology, Chiba Cancer Center, Chiba, Japan., Masaki Y; Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan., Iino M; Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan., Takizawa J; Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan., Maeda Y; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Yamamoto K; Department of Hematology, Okayama City Hospital, Okayama, Japan., Tamura S; Department of Hematology/Oncology, Kinan Hospital, Tanabe, Japan., Yoshida A; Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan., Yagi H; Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan., Yoshida I; Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan., Kitazume K; Department of Hematology, Showa General Hospital, Tokyo, Japan., Masunari T; Department of Infectious Diseases, Chugoku Central Hospital, Fukuyama, Japan., Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Kakinoki Y; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan., Suzuki R; Department of Oncology/Hematology, Innovative Cancer Center, Shimane University Hospital, Izumo, Japan., Yoshino T; Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Nakamura S; Department of Pathology and Biological Response, Nagoya University Graduate School of Medicine, Nagoya, Japan., Hatta Y; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan., Yoshida T; Member, Society of Lymphoma Treatment in Japan, Kashihara, Japan., Kanno M; Oncology Center, Nara Medical University Hospital, Kashihara, Japan.
Jazyk: angličtina
Zdroj: Hematological oncology [Hematol Oncol] 2021 Feb; Vol. 39 (1), pp. 51-59. Date of Electronic Publication: 2020 Oct 07.
DOI: 10.1002/hon.2809
Abstrakt: Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiuxetan ( 90 Y-IT) after re-induction therapy with BR in patients with previously treated FL. This study included adult patients with relapsed FL who had undergone one or two prior therapies. Re-induction therapy with BR was administered every 4 weeks up to 4-6 cycles. If patients achieved at least partial response, 90 Y-IT was administered as consolidation therapy. The primary endpoint was 2-year progression-free survival (PFS) after consolidation. A total of 24 FL patients (median age 60 years) who had undergone one (n = 17) or two (n = 7) prior treatments received BR. After BR therapy, 22 patients proceeded to consolidation with 90 Y-IT, resulting in an overall 88% response rate to the protocol treatment. Within a median observation period of 46.8 months, the estimated 2-year PFS rate after the consolidation among the 22 patients receiving 90 Y-IT was 59% (95% confidence interval [CI], 38%-77%). Patients whose remission after previous treatment had lasted ≥2 years had a significantly higher 2-year PFS rate than patients whose remission after previous treatment had been <2 years (68% vs. 33%, Wilcoxon p = 0.0211). Major adverse events during the protocol treatment and within 2 years after the consolidation were hematological toxicities, but they were generally acceptable. Consequently, the estimated 2-year overall survival after the consolidation was 95% (95% CI, 74%-99%). In conclusion, in a subset of patients with previously treated FL, 90 Y-IT consolidation after BR re-induction conferred a durable remission, indicating that consolidation therapy using 90 Y-IT may be a novel therapeutic option for patients with relapsed FL (UMIN000008793).
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: